AMIC Press Releases

AMIC Signs Exclusive Global license for "Sub-Critical System" to Produce Mo99

KENNEWICK, Wash., June 3, 2010 (GLOBE NEWSWIRE) -- Advanced Medical Isotope

Corporation ("AMIC") (OTCQB:ADMD), a company engaged in the production and distribution of

medical isotopes, is delighted to announce the execution of an exclusive world-wide license for

patented technology for a 'sub-critical system' relating to generating clinically relevant quantities of

radioisotopes (including Mo-99).

Pursuant to an option first granted to AMIC in June of 2008, AMIC has been working with Dr. John

Gahl, one of the inventors of the technology. AMIC announced in November, 2009, encouraging

results from initial tests conducted at the Idaho Accelerator Center at Idaho State University and

continues to run hundreds ofMCNPX computer runs, which have since been independently

confirmed and have created a commercial business case for going forward with utilizing the enhanced

technology.

It is expected that once the plant is completed, that this technology will afford AMIC the opportunity

to supply up to 50% of the Mo-99 needs of the United States.

United States patent applications 101141,171 titled "Method and Apparatus for Generating Thermal

Neutrons Using an Electron Accelerator and 12/364,942 titled "Radioisotope Production and

Treatment of Solution of Target Material", and continuing applications thereof are included within the

scope of the license.

"We believe that this is one tenific solution set for solving the United States' dire problem of having

no domestic production for the most widely used medical isotope, Molybdenum-99. I look forward to

AMIC mobilizing into production," stated Dr. John Gah!.

Dr. Robert Schenter, Chief Science Officer of AMIC, states, "1500 people die each day in the USA

from cancer. .. this license and the accompanying technology will greatly assist the USA from being

100% dependent on foreign sources for the critical isotope used in diagnosis, Mo-99, to being self

sufficient. There are about 40,000 procedures a day using medical isotopes, and the major suppliers in

the world are not in the USA! We here at AMIC are developing teclmology to assist this major health

care crises."

About Advanced Medical Isotope Corporation

Advanced Medical Isotope Corporation (AMIC) (OTCQB:ADMD) is a company engaged in the

production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic

application. AMIC's goal is to empower physicians, medical researchers, and ultimately patients by

providing them with essential medical isotopes that, until now, have not been feasible or economical,

in an effort to detect and cure human disease. For more information, please visit our website,

http://www.isotopeworld.com

SAFE HARBOR

The information posted in this release may contain forward-looking statements within the meaning of

the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the

words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects,"

"intends," and similar expressions. Forward-looking statements involve risks and uncertainties that

could cause results to differ materially from those projected or anticipated. These risks and

uncertainties include, but are not limited to, general economic and business conditions, effects of

continued geopolitical unrest and regional conflicts, competition, changes in technology and methods

of marketing, delays in completing various engineering and manufacturing programs, changes in

customer order patterns, changes in product mix, continued success in technological advances and

delivering technological innovations, shortages in components, production delays due to performance

quality issues with outsourced components, government agency rules and changes, and various other

factors beyond the Company's control.

CONTACT: Advanced Medical Isotope Corporation

James c. Katzaroff

509-736-4000

go to article

Report: Cancer expenses doubled since 1987

HealthImaging.com | May 10, 2010 | According to a study published online May 10 in Cancer, the medical costs of cancer have nearly doubled over the course of the past 20 years and as a result, the share of these costs paid for by private insurance and Medicaid have increased.

Health Economist Florence K. Tangka, PhD, and her colleagues from the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention in Atlanta, said that prior to their study, there had never been a comprehensive analysis of how aggregate cancer costs have changed over time.

Leveraging data from the 2001 through 2005 Medical Expenditure Panel Survey and the 1987 National Medical Care Expenditure Survey, the researchers estimated cancer-attributable medical expenditures by payor and type of service.

In doing so, two of the aforementioned trends were identified, as well as cancer costs shifting away from the inpatient setting, the authors wrote.

Tangka and colleagues determined that in 1987, the total medical cost of cancer (adjusted to 2007 U.S. dollars) was $24.7 billion.

Medicare financed approximately 33 percent of this total, followed by 17 percent paid out of pocket, other public payors, 7 percent and Medicaid approximately 1 percent, according to the researchers. Private payors were found to have financed the largest share, at 42 percent.

The total medical cost of cancer increased to $48.1 billion between 1987 and the 2001 to 2005 period and the number of reported cases rose, the authors wrote, which they partially attributed to new cases of cancer diagnosed among an aging population, as well as to an increase in the prevalence of cancer.

During this time period, Medicare financed approximately the same amount, rising a percentage to 34 percent. Other public payors dropped to 5 percent and Medicaid rose to 3 percent. Private insurance saw the greatest decrease however, financing 50 percent of the cost of cancer.

In addition, the authors found that the share of total cancer costs that resulted from inpatient admissions fell from 64.4 percent in 1987 to 27.5 percent in 2001 to 2005, representing a drop in inpatient costs from $15.9 billion to $13.2 billion over the course of this time period.

According to the researchers, this trend demonstrates that cancer treatments are increasingly being provided in outpatient settings.

Overall, Tangka and colleagues have concluded their findings to be positive, as they noted a 1.8 percent annual decline in cancer deaths beginning in 2002.

HealthyImaging.com

Staff writers

http://www.healthimaging.com/index.php?option=com_articles&view=article&id=22110

AMIC Receives Positive Results from Initial Tests of a Proprietary and Innovative Method for the Dom

AMIC is delighted to announce the encouraging results from initial tests conducted at Idaho State University (Pocatello, Idaho) in conjunction with researchers from the University of Missouri (Columbia, Missouri).

"Let there be little doubt about it -- thus far, we are proving exactly what we anticipated -- that AMIC expects its accelerator based proprietary technology to be first to market in the rush for domestic production of molybdenum-99 for medical purposes," stated Chief Science Officer Dr. Robert Schenter.

As stated in the 'Markey' Bill H.R. 3276: Molybdenum-99 is a critical medical isotope whose decay product technicium-99m is used in approximately two-thirds of all diagnostic medical isotope procedures in the United States, or 16 million medical procedures annually, including for the detection of cancer, heart disease, and thyroid disease, investigating the operation of the brain and kidney, imaging stress fractures, and tracking cancer stages."

While much of the country is focused on the economic crisis and the health care legislation, many physicians on the front lines are dealing with the very real isotope crisis, caused in part by the recent shutdown of the Chalk River reactor in Canada, which had previously supplied virtually all of the U.S. demand for Molybdenum-99.

"The current crisis is resulting in needless morbidity and mortality. The isotope shortage is preventing physicians from diagnosing and treating heart and cancer patients. This is resulting in unnecessary deaths and suffering," insisted Glen Farkas, MD, a practicing physician and Medical Advisor to Advanced Medical Isotope Corporation.

CEO James C. Katzaroff explained that "The technology we are developing is expected to be able to capture a significant portion of the United States domestic market. Further, AMIC anticipates being the first domestic producer as the time to build is expected to be much shorter than comparable reactor systems. Further, it appears that the production facility will have much lower costs associated with both build-out as well as with ongoing operations versus comparable reactor systems. In addition to that, this accelerator based approach is designed to be below criticality. It is significant to note that because this system employs LEU (low enriched uranium) it would comply with H.R. 3276, and unlike a nuclear reactor, this accelerator-driven system cannot go critical."

Advanced Medical Isotope Corporation is commencing in a second round of prototype tests.

Katzaroff further explained that "It is our wish and desire to have the first production facility in either Washington State or in Idaho and we have begun discussions and site selection utilizing optimal search parameters."

SAFE HARBOR
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with
outsurced components, and various other factors beyond the Company's control.

Contact:
Advanced Medical Isotope Corporation
James C. Katzaroff
509-736-4000

CANCER: Murray gets $1.25 million for Kennewick cancer research

U.S. Sen. Patty Murray announced that $1.25 million she included for cancer research at Advanced Medical Isotope Corp. of Kennewick has been included in the final version of the fiscal year 2010 Senate Energy and Water Development appropriations billl.

The bill has now been approved by both houses of Congress after passing the Senate today by a vote of 80-17 and will now head to the president, who Murray said is expected to sign it into law. “This funding will help maintain the Tri-Cities’ position at the cutting edge of scientific research and development,” said Murray, D-Wash. “I am pleased to support the work of Washington state scientific researchers as they work to develop new technologies to fight cancer.” Advanced Medical Isotope Corp.’s project will develop, test and conduct research needed for FDA premarket approval for a new polymer seed containing millions of tiny yttrium-90 microspheres. The seeds can be surgically implanted in tumors, just as radioactive metal seeds are placed in prostate and brain cancer patients.

http://www.tri-cityherald.com/945/story/754999.html

AMIC to Initiate Physical Testing of a Proprietary Method to Produce Mo-99

KENNEWICK, WA, June 12, 2009 - Advanced Medical Isotope Corporation, along with a senior industrial partner and the University of Missouri (MU) are collectively collaborating and preparing to test and develop prototype compact devices to produce radioisotopes which could supply clinical quantities of Mo-99 within a few years.

In June 2008, Advanced Medical Isotopes Corporation (AMIC) and the University of Missouri (MU) entered into an agreement to develop a compact device for producing medical radioisotopes. As was reported at that time:

"The University of Missouri holds intellectual property for a system than can generate clinically relevant quantities of radioisotopes (including Mo-99), the production of which normally requires a nuclear reactor. This can be done in a "sub-critical system" (technically and legally not a nuclear reactor, thus avoiding significant and costly regulations) with an infrastructure footprint similar to a commercial cyclotron facility. The partnership between MU and AMIC allows for a staged development of such a system to produce medical, research, and industrial isotopes. MU currently holds intellectual property for a device that generates neutrons in a tank filled with heavy water and fissile uranium material. Current simple models indicate that at least 500 curies (Ci) of Mo-99 would be available from such a system after a one week period of operation, and the potential exists for even higher production levels. More extensive modeling and simulations are necessary, however, to confirm this possibility. Significant quantities of other useful radioisotopes, such as various radio-iodines and radioactive xenon, are expected to be generated as well."

Ongoing model calculations have supported the viability of this mode of production. Indeed, proprietary methods of increasing the production yield to several thousand curies per week of Mo-99 have subsequently been built into the latest designs. The advantages of a having a modular, sub-critical system, a small footprint, and significantly lower costs than comparable reactor-producing methods makes this a very viable candidate to reliably supply clinically significant quantities of Mo-99 in the US and elsewhere. A number of strategically located units in North America and other continents could easily supply the projected demand for Mo-99 (and other fission isotopes) with less risk and increased reliability.

AMIC is moving to now test this method and build prototype systems. To this end, discussions have been entered into with a prospective industrial partner that could result in an operational system within as little as 2-4 years. To assist in this project, AMIC is pleased to announce that Dr. Nigel R. Stevenson will be joining the Company as a Senior Consultant. Dr. Stevenson brings the experience of having previously worked in both academia and with a number of commercial ventures in the field of isotope and radiochemical production. He has had oversight of building and running several large-scale isotope production systems in addition to getting new radiochemicals and radioactive products to market.

About Advanced Medical Isotope Corporation

Advanced Medical Isotope Corporation (AMIC) is a medical isotope production company engaged in the production and distribution of medical isotopes and medical isotope in vivo delivery systems for advanced diagnostic and non-surgical therapeutic application. AMIC's goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until now, have not been feasible or economical, in an effort to detect and cure human disease. For more information, please visit our website, http://www.isotopeworld.com

About the University of Missouri

The University of Missouri (MU) is home to over 28,000 students and offers 19 schools and colleges and more than 270 degree programs and over the past decade has performed over $2 billion in research. Research at MU has a $440 million impact on the state of Missouri and supports over 9,000 jobs. The University is also home to the MU Research Reactor (MURR), the largest research reactor operated by a university in the United States. MURR is a worldwide leader in the production of radioisotopes for research, industry and radiopharmaceutical applications and serves as a test-bed for physics testing and therapeutic studies that require high-intensity neutron beams. MURR is part of a public-private partnership which has built a facility to house a cyclotron for the production of PET isotopes and provide a facility for production of research isotopes. This will allow MU to supply a much-needed isotope to area medical centers for use in diagnosing and treating cancer and heart disease as well as expanding the types of radioisotopes available to university scientists.

SAFE HARBOR

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.

Contact:
Advanced Medical Isotope Corporation
James C. Katzaroff
509-736-4000

AMIC Announces Board of Director Appointment

Advanced Medical Isotope Corporation announced today the appointment of Dr. Michael Korenko to its Board of Directors.

Dr. Korenko was the Westinghouse Vice President in charge of the 300 and 400 areas, including the Fast Flux Testing Facility (FFTF) and all the engineering, safety analysis, and projects for the Hanford site. He was also the Executive Vice President of Closure for Safe Sites of Colorado at Rocky Flats. His most previous assignment was Chief Operating Officer for Curtiss-Wright, who produces the nuclear components for all the United States submarine and aircraft carriers as well as components for commercial nuclear power companies.

Dr. Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defense, reporting to Secretary Cap Weinberger. Mike Korenko currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.

Most relevant to AMIC, Dr. Korenko is the co-inventor with AMIC Chief Science Officer Dr. Robert Schenter, of a patent-pending process converting nuclear waste into medical isotopes.

``We are quite pleased to have Dr. Korenko join our Board of Directors,'' said Jim Katzaroff, CEO of Advanced Medical Isotope Corporation. ``As an industry veteran, Mike will provide additional strength and depth to our organization, assisting us on multiple fronts, including capitalizing technology developments, strategic positioning, and expanding revenue generation.''

About AMIC

Advanced Medical Isotope Corporation (AMIC) is a medical isotope production company engaged in the production and distribution of medical isotopes and medical isotope in vivo delivery systems for advanced diagnostic and non-surgical therapeutic applications. AMIC's goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until now, have not been feasible or economical, in an effort to detect and cure human disease.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words ``may,'' ``will,'' ``should,'' ``plans,'' ``explores,'' ``expects,'' ``anticipates,'' ``continue,'' ``estimate,'' ``project,'' ``intend,'' and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.

Contact:
          Advanced Medical Isotope Corporation
          James C. Katzaroff, CEO
          509-736-4000

Read article online

Read article in PDF

AMIC Director Significantly Increases Stake

KENNEWICK, Wash., March 16, 2009 - Advanced Medical Isotope Corporation (``AMIC'') (Other OTC:ADMD.PK - News), a company engaged in the production and distribution of medical isotopes, announced today that one of its directors, Carl Cadwell, converted 95,000 shares of AMIC's Series A Preferred Stock into 10,857,142 shares of the Company's common stock.

The Series A Preferred Shares purchased by Dr. Cadwell were originally issued in September, 2006, to Utek Corporation for AMIC's purchase of technology from Utek. The Series A Preferred Stock conversion was based on AMIC's common stock's average closing price for the ten trading days before the date of conversion.

CEO James C. Katzaroff said, ``This purchase from Utek and subsequent conversion of our Series A Preferred Stock by director Carl Cadwell significantly reduces the overhang on our common stock. Furthermore, while increasing his stake to approximately 40% of AMIC, we sincerely appreciate Mr. Cadwell's continued confidence in AMIC's direction and management.''

About AMIC

Advanced Medical Isotope Corporation(AMIC) is a medical isotope production company engaged in the production and distribution of medical isotopes and medical isotope in vivo delivery systems for advanced diagnostic and non-surgical therapeutic applications. AMIC's goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until now, have not been feasible or economical, in an effort to cure human disease.
For more information, please visit our website, http://www.isotopeworld.com

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include,but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.

Contact:

Advanced Medical Isotope Corporation
James C. Katzaroff, CEO
509-736-4000
Source: Advanced Medical Isotope Corporation

AMIC Wins DOE grant to pursue development of compact-systems technology

KENNEWICK, WA., Jan. 21, 2009(PRIME NEWSWIRE)—Advanced Medical Isotope Corporation (“AMIC”) (Other OTC:ADMD.PK-News)(http://www.isotopeworld.com), a company engaged in the production and distribution of medical isotopes, announced today that it has received funding approval, together with the Kharkiv Institute of Physics and Technology (KIPT) of the Ukraine, and the Department of Energy’s (DOE) Pacific Northwest National Laboratory (PNNL), in Richland, Washington, managed by Battelle, for a two- year project to develop and bring to market an innovative compact-systems technology for producing critically needed medical isotopes. The DOE will support the project with a development grant worth $760,000.

Relative to nuclear reactors and large accelerators, compact systems are expected to reduce the overall cost and increase the flexibility needed to produce smaller amounts of research and commercial isotopes for applications in diagnostic and therapeutic nuclear medicine. The new production method funded by this project is based on the Alternative Method for Producing Medical Isotopes (AMPMI) technology being developed at the Kharkiv Institute in the Ukraine. The AMPMI method generates an intense neutron beam at high fluence rate under controlled conditions, with an advanced target design for efficient production of neutron-rich medical isotopes.

“The AMPMI neutron technology complements our current proton LINAC at our first production facility in Kennewick, Washington,” said Jim Katzaroff, CEO at AMIC. “We anticipate that the AMPMI neutron technology will provide the opportunity to produce a wide variety of medical isotopes on a smaller scale, closer to the point of use, than isotope production in nuclear reactors.”

Nearly 20 million medical isotope procedures are performed annually in the United States, including cardiac evaluations, infection imaging, and cancer treatment. Unfortunately, most medical isotopes are produced by nuclear reactors in foreign countries and are imported. This situation has led to shortages and supply interruptions, which adversely impact patient health care.

One alternative is domestic isotope production using versatile, cost-effective electronic systems for neutron generation instead of aging nuclear reactor technologies.

“Politicians talk about the need to improve access to health care in this country,” said Katzaroff. I respectfully submit that, unless we develop the means to produce these critical medical isotopes on our own soil, then the U.S. health care industry will continue to find itself in the very same dangerous predicament as the energy industry with its dependence on foreign sources of oil. AMIC is committed to developing and commercializing domestic sources of medical isotope production to alleviate that dependence.”

About KIPT

Created in 1928 for the purpose of developing urgent lines of research in nuclear physics and solid-state physics. Since the disintegration of the USSR, the Institute is currently active in the fields of solid-state physics, plasma physics, nuclear physics, and plasma electronics. More than 400 scientists carry out fundamental research and support with nearly 300 Candidates and 80 Doctors of Science.

About PNNL

Pacific Northwest National Laboratory is a DOE Office of Science national laboratory that solves complex problems in energy, national security and the environment, and advances scientific frontiers in the chemical, biological, materials, environmental and computational sciences. PNNL employs 4,200 staff, has a $750 million annual budget, and has been managed by Columbus (Ohio)-based Battelle since the lab’s inception in 1965.

About AMIC

Advanced Medical Isotope Corporation (AMIC) is a medical isotope production company engaged in the production and distribution of medical isotopes and medical isotope in vivo delivery systems for advanced diagnostic and non-surgical therapeutic application. AMIC’s goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until now, have not been feasible or economical, in an effort to detect and cure human disease.

For more information, please visit our website, http://www.isotopeworld.com

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company’s control.

CONTACT:

Advanced Medical Isotope Corporation

James C. Katzaroff, CEO

509-736-4000

AMIC to present at United Pharmacy Partners 2008 Annual Meeting

Kennewick, WA – September 25, 2008 – Advanced Medical Isotope Corporation (“AMIC”) (OTHER OTC: ADMD, http://www.isotopeworld.com), a company engaged in the production and distribution of medical isotopes, has accepted an invitation to present at the United Pharmacy Partners, Inc.’s (UPPI) 2008 Annual Meeting. The event will be held September 24-27, 2008 at Disney’s Contemporary Resort Walt Disney Worldâ in Orlando, Florida. James C. Katzaroff, AMIC’s chief executive, will give a presentation entitled, “AMIC: Solution to Impending U.S. Isotope Supply Shortage,” at 8:00 AM EDT on Friday, September 26, 2008.

During his presentation, Mr. Katzaroff will discuss AMIC’s solutions to the impending shortage of medical isotopes in the United States. Today, the nation imports about 90% of the medical isotopes used in hospitals and clinics. Currently, more than fifteen million nuclear medicine procedures are performed each year in the U.S. According to the official website of Citizens for Medical Isotopes (CMI), a national, non-profit organization, current U.S. production resources are not adequate to meet the increasing needs for isotope use in research, diagnosis, and treatment.

“AMIC is pleased to share with the UPPI community our progress concerning the issue of medical isotope shortage in the U.S.,” said Mr. Katzaroff. “Our recent shipments of short-lived radioisotopes from our Kennewick, Washington production center, and the establishment of key relationships with universities and national laboratories illustrate that we are successfully addressing this serious and growing medical need.”
About UPPI

Established in 1998, UPPI has become a leader in traditional nuclear medicine and in the rapidly growing nuclear and PET pharmacy industries. Representing more than 100 operating sites across the country, UPPI provides its members national strength in buying relationships as well as access to customizable local programs that advance the professionalism of the industry.

About Advanced Medical
Advanced Medical Isotope Corporation (AMIC) is a medical isotope production company engaged in the production and distribution of medical isotopes and medical isotope in vivo delivery systems for advanced diagnostic and non-surgical therapeutic application. AMIC’s goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until now, have not been feasible or economical, in an effort to detect and cure human disease. For more information, please visit our website, http://www.isotopeworld.com.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company’s control.

CONTACT:

Advanced Medical Isotope Corporation
James C. Katzaroff
509-736-4000

The Investor Relations Group
Erika Moran
212-825-3210
Lynn Granito/Steven Melfi
212-825-3210

http://biz.yahoo.com/bw/080925/20080925005327.html?.v=1

View PDF

AMIC Appoints Internationally-Renowned Nuclear Expert, Dr. Alan Waltar, as Scientific Advisor

KENNEWICK, Wash., Aug. 12, 2008 (PRIME NEWSWIRE) -- Advanced Medical Isotope Corporation (``AMIC'') (Other OTC:ADMD.PK - News) (http://www.isotopeworld.com), a company engaged in the production and distribution of medical isotopes, announced today that it has appointed Dr. Alan Waltar as chairman of its Scientific Advisory Committee. AMIC Chief Science Officer, Dr. Robert Schenter, has been named Chair Emeritus.

"We are delighted in welcoming Dr. Waltar to our Scientific Advisory Committee,'' said James C. Katzaroff, AMIC's chairman and chief executive officer. ``Dr. Waltar is an esteemed member of the international nuclear community and a well-respected proponent of advancing America's development of nuclear medicine. His nuclear expertise will help strengthen AMIC's R&D and production methods and his nuclear medicine connections will serve in helping us to reach out to more physicians, medical researchers and patients on the life-saving benefits of medical isotopes.''

Most recently, Waltar served as director of Nuclear Energy for the Pacific Northwest National Laboratory (PNNL) in Richland, Wash. Since 2004, he has continued his affiliation with PNNL as a Senior Advisor. Waltar's other professional appointments include director of International Programs at Advanced Nuclear Medical Systems; manager of various Fast Reactor Safety and Fuels Organizations of Westinghouse Hanford Company; and as professor and department head of Nuclear Engineering at Texas A&M University.

His other teaching experience includes stints at the Joint Center for Graduate Study in Richland Wash., the University of Virginia, and Los Alamos National Laboratory. Formerly the president of the American Nuclear Society, Waltar has served on a number of international nuclear science and radiation panels, societies, and committees. He is the author of three books: Fast Breeder Reactors, America the Powerless: Facing Our Nuclear Energy Dilemma, and Radiation and Modern Life: Fulfilling Marie Curie's Dream, and has penned over 70 open literature papers.

Dr. Waltar earned his M.S. in Nuclear Engineering from M.I.T. and his PhD in Engineering Science from the University of California, Berkeley.

About Advanced Medical Isotope Corporation

Contact:
          Advanced Medical Isotope Corporation
          James C. Katzaroff
          509 736 4000

--------------------------------------------------------------------------------
Source: Advanced Medical Isotope Corporation

http://biz.yahoo.com/pz/080812/148451.html